1. Home
  2. DLR vs ARGX Comparison

DLR vs ARGX Comparison

Compare DLR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLR
  • ARGX
  • Stock Information
  • Founded
  • DLR 2004
  • ARGX 2008
  • Country
  • DLR United States
  • ARGX Netherlands
  • Employees
  • DLR N/A
  • ARGX 1639
  • Industry
  • DLR Real Estate Investment Trusts
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DLR Real Estate
  • ARGX Health Care
  • Exchange
  • DLR Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • DLR 59.4B
  • ARGX 51.1B
  • IPO Year
  • DLR 2004
  • ARGX 2017
  • Fundamental
  • Price
  • DLR $167.14
  • ARGX $821.97
  • Analyst Decision
  • DLR Buy
  • ARGX Strong Buy
  • Analyst Count
  • DLR 19
  • ARGX 18
  • Target Price
  • DLR $197.72
  • ARGX $813.82
  • AVG Volume (30 Days)
  • DLR 1.6M
  • ARGX 351.8K
  • Earning Date
  • DLR 10-23-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • DLR 2.80%
  • ARGX N/A
  • EPS Growth
  • DLR 210.04
  • ARGX N/A
  • EPS
  • DLR 3.87
  • ARGX 18.75
  • Revenue
  • DLR $5,841,035,000.00
  • ARGX $3,120,821,000.00
  • Revenue This Year
  • DLR $11.06
  • ARGX $81.74
  • Revenue Next Year
  • DLR $10.85
  • ARGX $31.91
  • P/E Ratio
  • DLR $45.01
  • ARGX $39.70
  • Revenue Growth
  • DLR 8.67
  • ARGX 88.04
  • 52 Week Low
  • DLR $129.95
  • ARGX $510.06
  • 52 Week High
  • DLR $198.00
  • ARGX $855.46
  • Technical
  • Relative Strength Index (RSI)
  • DLR 50.69
  • ARGX 66.55
  • Support Level
  • DLR $168.72
  • ARGX $807.42
  • Resistance Level
  • DLR $182.48
  • ARGX $855.46
  • Average True Range (ATR)
  • DLR 3.82
  • ARGX 16.35
  • MACD
  • DLR 0.06
  • ARGX -1.82
  • Stochastic Oscillator
  • DLR 38.38
  • ARGX 74.83

About DLR Digital Realty Trust Inc.

Digital Realty owns and operates over 300 data centers worldwide. It has nearly 40 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to "cold shells," where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. The company operates as a real estate investment trust.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: